New York, NY (PRWEB) April 16, 2014

A federal Panel has set a date next month to hear oral arguments on whether to transfer all pending and future AndroGel lawsuit (http://www.testosteronelawsuit2014.com/) filings to the U.S. District Court, Northern District of Illinois, Bernstein Liebhard LLP reports.

According to a recent Order, the U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear oral arguments on May 29th, 2014 in Chicago that relate to the potential consolidation of testosterone lawsuits over AndroGel, a Low T hormone-raising therapy. The Panels Order on April 14th was issued in response to a motion from plaintiffs last month that requested the coordination of AndroGel claims in Illinois federal court. Among other things, the March 28th brief contended that the creation of a multidistrict litigation was necessary to handle the thousands of similar claims over the medication that may be filed in the future. AndroGel lawsuits in this jurisdiction allege strokes, heart attacks, dangerous blood clots and other serious cardiovascular problems, court documents indicate. (In Re: AndroGel Product Liability Litigation, No. 36, JPML)

We are looking forward to the federal Panels upcoming hearing on whether to coordinate AndroGel lawsuits in the Southern District of Illinois, as our lawyers continue to hear from men who were allegedly injured by the Low T treatment, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential AndroGel lawsuit evaluations to men who allegedly suffered heart attacks, strokes, deep vein thrombosis or pulmonary embolism after taking the medication.

Testosterone Lawsuits over AndroGel

As of March 2014, court documents indicate that some 30 AndroGel lawsuits had been filed in the U.S. District Court, Northern District of Illinois on behalf of men who took the prescription medication. The plaintiffs motion from that month states that a number of additional testosterone lawsuits were pending in Pennsylvania and Colorado federal courts.

In speaking to the benefits of a federal AndroGel lawsuit litigation, individuals in these cases say its creation would preserve the resources of the court, parties and witnesses and help avoid duplicative discovery in similar claims over the drug, as well as inconsistent rulings from judges.

All the lawsuits now filed over AndroGel in Illinois federal court allege similar cardiovascular problems caused by the hormone-raising therapy that was originally approved to treat low levels of the hormone, also known as hypogonadism, in conjunction with another medical condition. According to claims however, the medication is frequently prescribed for uses not cleared by the U.S. Food and Drug Administration (FDA), and is instead given to men suffering from low libido, fatigue and other common symptoms of aging. This practice is referred to as disease mongering, according to AndroGel lawsuit plaintiffs who accuse its manufacturer of placing sales of its product above patient safety.

All of the claims now filed over AndroGel and other similarly-designed testosterone treatment therapies were filed after the FDA issued a public health alert about the safety of certain Low T medications. The federal agencys warning was released on January 31, 2014 after the findings of two studies linked the use of drugs like AndroGel, Testim and Axiron to heart attacks, strokes and sudden cardiac death in certain men.

Men who allegedly suffered heart attacks, strokes, dangerous blood clots, deep vein thrombosis or pulmonary embolism after taking a Low T treatment may be eligible to file a testosterone lawsuit against its manufacturer. To learn more about the fast-developing AndroGel lawsuit litigation, please visit Bernstein Liebhard LLPs website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092

Read this article:

Federal Panel Schedules Hearing on Possible Creation of AndroGel Lawsuit Litigation in the Northern District of ...